Compare UNB & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | BMEA |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 132.6M |
| IPO Year | 1999 | 2021 |
| Metric | UNB | BMEA |
|---|---|---|
| Price | $23.35 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 2.7K | ★ 2.0M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | 25.52 | ★ 69.19 |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $0.87 |
| 52 Week High | $26.41 | $2.99 |
| Indicator | UNB | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 39.73 |
| Support Level | $22.95 | $1.17 |
| Resistance Level | $24.22 | $1.47 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 7.81 | 14.58 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.